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Abstract
Lack of substantial progress in effective treatment of
glioblastoma multiforme has led investigators to explore
unconventional treatment options including the use of
tumour treating fields and oncolytic virotherapy. Herein
the authors have reviewed some of the recent literature
on oncolytic virotherapy for the treatment of glioblastoma
multiforme.
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Introduction
The year is 2005 and Temozolomide becomes the first
major breakthrough to be allowed FDA approval for
glioblastoma treatment with significant improvement in
survival in the preceding two decades. This treatment saw
an improvement in overall survival from a median of 6.9
months in 1995-96 to 10.3 months in those diagnosed
between 2010-15 with 2-year survival peaking to 18%.1
Several known and newly discovered chemotherapy
agents have been tested with marginal or no improvement
in overall survival.2 A major field in glioblastoma research
is immunomodulation. Amongst the many methods
currently under review, using a pathogenic virus to
stimulate the immune response into killing tumour cells
holds significant promise.
Review of evidence
The idea is neither new nor unique and is derived from
fairly well established historical evidence of spontaneous
tumour regression following immunization or incidental
viral infection. For directed therapy, these viruses must
infect only the target of interest, must not damage normal
cells and be phased out of the host once its job is done.3
Such a combination is hardly found in nature.Scientists
therefore, have turned to genetic engineering for the task.
Such viruses are known as oncolytic and the neurotropic
poliovirus was considered for this purpose in the 1990s.
The prototype oncolytic poliovirus, termed PVS-RIPO, is
the live attenuated poliovirus type 1 (Sabin) containing a
heterologous IRES (internal ribosome entry site) derived
of human rhinovirus type 2 (HRV2).4 This chimera is capable
of entering and lysing tumour cells but cannot infect or
replicate in normal cells that are capable of triggering an
immune response, which tumour cells cannot. Genetic
stability was ensured following serial transmission through
HeLa cell lines, which are one of the oldest and most
commonly used cell lines.5
Preliminary studies in animals showed the virus to be
effective in eliminating neuroblastoma and glioblastomas
in mice to certain success. In these early studies, tumour
inoculum would be placed in mice and allowed to grow
followed by intra-tumoural injection of PVSRIPO.6,7 The
results were very promising and shortly trials using human
subjects were initiated by Gromeier and colleagues at
Duke University. In a landmark paper published in 2018,
they described phase II trials involving a direct intra-
tumoural inoculation of PVS-RIPO. The study lasted from
May 2012 to May 2017 and involved 61 patients with
recurrent glioblastoma. These patients were consecutively
chosen after a single recurrence of glioblastoma with a
KPS of no less than 70, a contrast enhancing tumour
volume greater than 1 cm3 and less than 5.5 cm3. A single
stereotactic biopsy was taken prior to placement of
catheter to deliver PVS-RIPO into the tumour for genetic
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Figure a) b) MRI T1WI, axial sections, pre and post-contrast images show a
heterogeneously enhancing mass lesion with central necrosis
and intense perilesional oedema, characteristic radiological
features of glioblastoma multiform
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analysis and confirmation. Inoculum volumes (3.25 ml)
were administered with a pump and imaging was acquired
4 hours after administration and thereafter at regular
intervals.8
Results of the trial were promising with overall survival
plateauing at 21% at 24 months in the PVS-RIPO group
while overall survival continued to decline in the historical
group. This was favourable to outcomes following
treatment with Nova-TTF.9 This study also showed patients
to have a durable radiographic response following infusion
with tumour volumes diminishing over time. Further work
is required to determine which genetic variant of
glioblastoma is most amenable to this treatment as new
data comes to light regarding the molecular and genetic
heterogeneity of this elusive and fatal disease.10
Conclusion
Based on current evidence, we strongly believe that
oncolytic virus therapy has an evolving role in glioblastoma
management. Current evidence points towards its likely
benefit in significantly improving survival in recurrent
disease but it may also have a role to play in newly
diagnosed glioblastoma as a means of either primary
therapy of volume reduction prior to surgery in order to
convert unresectable disease into one that is amenable
to surgery.
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